

For immediate release:

National Institutes of Health Awards Yaso Biotechnology SBIR Grant

New Product Aimed To Prevent Sexually Transmitted Infections and Unplanned Pregnancies

Phoenix, AZ, March 7, 2011 -- Yaso Biotechnology Inc. today announced that it has been awarded a Phase I SBIR grant for \$285,000 from the National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) to support further preclinical development of a PPCM-based vaginal microbicide. NIH has invested approximately \$2.2 million in this drug and Yaso, which now holds the worldwide license for this drug, was previously awarded an STTR grant in excess of \$150,000 to begin preclinical development.

PPCM is an anti-infective drug that blocks the fusion and entry of virus or bacteria into healthy cells. Preclinical studies show it is effective against Herpes Simplex (HSV) and all clades of HIV as well as Gonorrhea. It also promises to be a safe contraceptive. While there are many potential topical applications for this drug, Yaso will seek approval for this drug first as a contraceptive gel that prevents sexually transmitted infections (STIs). This application is important because there are only two products today that can protect a woman from infection – the male and female condoms.

“We continue to make significant progress toward our goals of launching PPCM gel as a new product that is contraceptive, protects women from contracting an STI all while being aesthetically pleasing and low cost. And, we are honored to receive our second grant from the NIH-NIAID,” said Mary Frost, founder and CEO of Yaso Biotechnology. “We appreciate the confidence NIH shares with our research team in the scientific, commercial and humanitarian potential of our product. We are poised to dramatically reduce healthcare costs, both private and governmental, globally while giving couples a much needed product to help them lead healthy lives.”

Following clinical trials and approval by the Food and Drug Administration (FDA), PPCM is expected to be commercialized as an over-the-counter vaginal gel used by women prior to intercourse. Yaso Biotechnology licensed the worldwide rights to PPCM from Rush University Medical Center and the University of Illinois at Chicago.

There is currently no approved product, other than condoms, that provides protection from STIs, sexually transmitted HIV/AIDS, and unplanned pregnancies. According to the Centers for Disease Control, there were fifteen million new STI cases in the United States in 2004, with twenty-five percent occurring in teenagers. Forty-five million Americans live with an incurable STI. Globally, there were over three hundred million new STI cases (not including HIV/AIDS) during the past year. The single highest mode of HIV transmission is heterosexual intercourse.

About Yaso

Yaso Biotechnology Inc.® is a privately-held Texas “C” corporation developing a proprietary drug platform to improve global health. Yaso’s products will offer significant

innovations in the fields of reproductive health and epidemic disease prevention, while being relatively inexpensive to produce, and easy to distribute. Yaso's development partners include the University of Illinois at Chicago, Rush University Medical Center, and other leading scientific organizations and researchers. Additional information about Yaso is available at <http://www.yasobiotech.com>.

Contact:

Mary Frost, CEO, President
Yaso Biotechnology
1928 East Highland Ave.
Ste. F-104, #182
Phoenix, AZ 85016
(480) 231-3361
mfrost@yasobiotech.com

###